Recombinant human epidermal growth factor: Difference between revisions
No edit summary |
Undid revision 630262589 by 66.82.162.13 (talk) |
||
| Line 3: | Line 3: | ||
'''Heberprot-P''' is a drug developed by Scientists at the Center for Genetic Engineering and Biotechnology (CIGB) in Cuba as a cure for [[diabetic foot ulcer]].{{citation needed|date=December 2013}} The product contains [[epidermal growth factor]] (EGF) to be applied by intra-lesional injections directly in the wound site.<ref>{{cite web|url=http://heberprot-p.cigb.edu.cu/index.php?option=com_content&view=article&id=17&Itemid=32&lang=en |title=Prescription Information |publisher=Center for Genetic Engineering and Biotechnology, Ave. 31 e/ 158 y 190, Cubanacán, Playa La Habana, Cuba |year=2010|accessdate=2012-09-08}}</ref><ref>{{cite journal |title=Heberprot-P: a novel product for treating advanced diabetic foot ulcer |last=Berlanga |first=J. |last2=Fernández |first2=J. I. |last3=López |first3=E. |last4=López |first4=P. A. |last5=del Río |first5=A. |last6=Valenzuela |first6=C. |last7=Baldomero |first7=J. |last8=Muzio |first8=V. |last9=Raíces |first9=M. |last10=Silva |first10=R. |last11=Acevedo |first11=B. E. |last12=Herrera |first12=L. |journal=[[MEDICC|MEDICC Review]] |year=2013 |volume=15 |issue=1 |pages=11–15 |pmid=23396236}}</ref> It has been found to "promote granulation and healing in advanced diabetic foot ulcers".<ref>{{cite web|url=http://onlinelibrary.wiley.com/doi/10.1111/j.1742-481X.2009.00641.x/full |title=Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study |publisher=International Wound Journal |date=December 2009|pages= 432–443| doi= 10.1111/j.1742-481X.2009.00641.x |accessdate=2012-09-08}}</ref> |
'''Heberprot-P''' is a drug developed by Scientists at the Center for Genetic Engineering and Biotechnology (CIGB) in Cuba as a cure for [[diabetic foot ulcer]].{{citation needed|date=December 2013}} The product contains [[epidermal growth factor]] (EGF) to be applied by intra-lesional injections directly in the wound site.<ref>{{cite web|url=http://heberprot-p.cigb.edu.cu/index.php?option=com_content&view=article&id=17&Itemid=32&lang=en |title=Prescription Information |publisher=Center for Genetic Engineering and Biotechnology, Ave. 31 e/ 158 y 190, Cubanacán, Playa La Habana, Cuba |year=2010|accessdate=2012-09-08}}</ref><ref>{{cite journal |title=Heberprot-P: a novel product for treating advanced diabetic foot ulcer |last=Berlanga |first=J. |last2=Fernández |first2=J. I. |last3=López |first3=E. |last4=López |first4=P. A. |last5=del Río |first5=A. |last6=Valenzuela |first6=C. |last7=Baldomero |first7=J. |last8=Muzio |first8=V. |last9=Raíces |first9=M. |last10=Silva |first10=R. |last11=Acevedo |first11=B. E. |last12=Herrera |first12=L. |journal=[[MEDICC|MEDICC Review]] |year=2013 |volume=15 |issue=1 |pages=11–15 |pmid=23396236}}</ref> It has been found to "promote granulation and healing in advanced diabetic foot ulcers".<ref>{{cite web|url=http://onlinelibrary.wiley.com/doi/10.1111/j.1742-481X.2009.00641.x/full |title=Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study |publisher=International Wound Journal |date=December 2009|pages= 432–443| doi= 10.1111/j.1742-481X.2009.00641.x |accessdate=2012-09-08}}</ref> |
||
Heberprot-P is indicated for the treatment of poor prognosis of deep, extensive, and terminal DFU not responding to comprehensive and/or extensive conventional methods, particularly in grades 3, 4 and 5 of Wagner's Classification with average ulcer size bigger than 20 cm<sup>2</sup>, of both neuropathic and ischemic etiology with high risk amputation.<ref>http://scielo.sld.cu/scielo.php?pid=S1027-28522010000200005&script=sci_arttext<\ref>. |
Heberprot-P is indicated for the treatment of poor prognosis of deep, extensive, and terminal DFU not responding to comprehensive and/or extensive conventional methods, particularly in grades 3, 4 and 5 of Wagner's Classification with average ulcer size bigger than 20 cm<sup>2</sup>, of both neuropathic and ischemic etiology with high risk amputation.<ref>http://scielo.sld.cu/scielo.php?pid=S1027-28522010000200005&script=sci_arttext<\ref>. Clinical studies in 344 patients with advanced diabetic foot ulcers (Wagner´s grade 3 or 4, median size >20 cm2, ischemic ulcers not excluded) have shown that injected recombinant EGF has the potential to promote complete granulation in more than 80%, with complete wound healing (re-epithelialization) in more than 50% of subjects usually unresponsive to other treatments. Injected recombinant EGF has the potential to reduce amputation rates, with a considerable personal and public health improvement, including longer survival.<ref>https://trpnppo.com/Documents/news/oncology/2013-8-12_782.pdf</ref> |
||
==Clinical trials and use== |
==Clinical trials and use== |
||
Revision as of 17:38, 19 October 2014
 | This article needs additional citations for verification. (October 2014) |
 | This article needs more links to other articles to help integrate it into the encyclopedia. (June 2013) |
Heberprot-P is a drug developed by Scientists at the Center for Genetic Engineering and Biotechnology (CIGB) in Cuba as a cure for diabetic foot ulcer.[citation needed] The product contains epidermal growth factor (EGF) to be applied by intra-lesional injections directly in the wound site.[1][2] It has been found to "promote granulation and healing in advanced diabetic foot ulcers".[3]
Heberprot-P is indicated for the treatment of poor prognosis of deep, extensive, and terminal DFU not responding to comprehensive and/or extensive conventional methods, particularly in grades 3, 4 and 5 of Wagner's Classification with average ulcer size bigger than 20 cm2, of both neuropathic and ischemic etiology with high risk amputation.Cite error: A <ref> tag is missing the closing </ref> (see the help page).
Clinical trials and use
The drug is currently in use in Cuba, Argentina, Colombia, Costa Rica, Ecuador, Guatemala, Mexico, Panama,[4][verification needed] Paraguay, Peru, Uruguay, Venezuela, Russia, Turkey[5] and in the Domenican Republicand, Vietnam, and the Philippines. Heberprot-P is protected by World patent WO PCT/CU2002/000011.[6]As of July 2012, China has started advanced stage-three tests of the drug, along with colleagues at 100 hospitals throughout the European Union. These trials are the first time Cuban scientists have undertaken advanced clinical trials in developed countries.[7]
The drug has been available in Algeria since 2008, and has seen use in 31 hospitals in the country.[citation needed] It was used on 314 patients, with a success rate of 90%.[citation needed] A local firm has applied to manufacture the drug in Algeria.[8][better source needed]
In South-east Asian countries such as Vietnam and the Philippines, the drug is being used as an advanced wound care healing drug and may be accessed through wound care clinics or wound care specialists among hospitals.[citation needed]
References
- ^ "Prescription Information". Center for Genetic Engineering and Biotechnology, Ave. 31 e/ 158 y 190, Cubanacán, Playa La Habana, Cuba. 2010. Retrieved 2012-09-08.
- ^ Berlanga, J.; Fernández, J. I.; López, E.; López, P. A.; del Río, A.; Valenzuela, C.; Baldomero, J.; Muzio, V.; Raíces, M.; Silva, R.; Acevedo, B. E.; Herrera, L. (2013). "Heberprot-P: a novel product for treating advanced diabetic foot ulcer". MEDICC Review. 15 (1): 11–15. PMID 23396236.
- ^ "Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study". International Wound Journal. December 2009. pp. 432–443. doi:10.1111/j.1742-481X.2009.00641.x. Retrieved 2012-09-08.
- ^ "Technical File in the Public Health Database" (in Spanish). Comité Técnico Nacional Interinstitucional. Retrieved October 19, 2014.
- ^ "Heberprot-P registered in Turkey". Granma International. September 29, 2014. Retrieved October 19, 2014.
- ^ http://www.google.com/patents/CA2470971C?cl=en
- ^ "China, Russia to test Cuban diabetes drug". Xinhua English. 2012-07-20. Retrieved 2012-09-09.
- ^ "L'Heberprot-P sauve 196 malades en Algérie: Traitement contre l'ulcère du pied diabétique". DjaZairess.com in French. 2009-12-09. Retrieved 2014-06-18.